Institute of Post Graduate Medical Education and Research
9 imported, source-linked research records. All imported publication dates.
9 matching research records
Topic: Canagliflozin and SGLT2. Only records linked to Institute of Post Graduate Medical Education and Research are included. Historical ingestion is still running; these are imported records, not a count of all research worldwide.
Showing 1–9 of 9 matching records. Counts update as records arrive.
Translating localized renal reprogramming to systemic protection: A comprehensive review of SGLT2 inhibitors in cardiovascular-kidney-metabolic syndrome
September 1, 2026 · 0 citations · Open access
Open original record →COMPARATIVE EFFICACY OF SODIUM–GLUCOSE COTRANSPORTER-2 INHIBITORS VERSUS PLACEBO ON CARDIOVASCULAR MORTALITY IN ADULTS WITH HEART FAILURE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
March 15, 2026 · 0 citations · Open access
Open original record →Dapagliflozin induces corneal nerve regeneration in subjects with type 2 diabetes by altering the AGE/RAGE pathway
December 1, 2025 · 0 citations · Open access
Open original record →Effect of Sodium Glucose Transporter 2 Inhibitor (SGLT2i) on Peak Left Atrium Strain in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) and its Correlation with N - Terminal Pro B Type Natriuretic Peptide (NT pro BNP) Level : A Follow Up Study
November 14, 2025 · 0 citations · Open access
Open original record →Abstract 4371800: 37,500 man-years of clinical expertise validate the cardio-metabolic benefits of empagliflozin-linagliptin in type 2 diabetes: findings from the amplified consensus
November 3, 2025 · 1 citations
Open original record →SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis
March 1, 2023 · 35 citations · Open access
Open original record →SGLT2 Inhibitors in the Management of Chronic Kidney Disease: An Expert Consensus
October 1, 2022 · 3 citations · Open access
Open original record →Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy
June 1, 2020 · 53 citations · Open access
Open original record →Role of metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug therapy in glycemic control, weight loss, and euglycemia in diabesity: A real-world experience
January 1, 2019 · 14 citations · Open access
Open original record →